Principal Investigators

    Salminen Outi


    University of Helsinki

    Contact information of lead PI



    Title of project or programme

    Distinct nicotinic acetylcholine receptors in dorsal and ventral striatum: Basis for novel therapies of Parkinson's disease

    Source of funding information

    Academy of Finland

    Total sum awarded (Euro)

    € 433,299

    Start date of award


    Total duration of award in years



    Research Abstract

    Parkinson´s disease is levodopa. However, levodopa treatment is plagued by adverse effects, especially dyskinesias that affect the whole body. Presently, there is no effective drug therapy against dyskinesias. In animal models, it has been shown that nicotinic drugs could be effective in treating dyskinesias. This study aims at clarifying what are the mechanisms of levodopa-induced dyskinesias and, further, how nicotine elicits its antidyskinetic effect. The aim of the proposed research is to build the basis for development of improved drug therapy for currently poorly treated aspects of Parkinson´s disease.

    Further information available at:

Types: Investments < €500k
Member States: Finland
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF